m6A methylation regulators and ncRNAs in osteosarcoma: Potential therapeutic strategies.

IF 4.3 3区 材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2024-10-25 DOI:10.1016/j.pbiomolbio.2024.10.003
Ce Shi, Lei Chen, Kui Huang, Guanghui Yang, Tingting Shi, Jinshuang Li, Hongbing Zheng
{"title":"m6A methylation regulators and ncRNAs in osteosarcoma: Potential therapeutic strategies.","authors":"Ce Shi, Lei Chen, Kui Huang, Guanghui Yang, Tingting Shi, Jinshuang Li, Hongbing Zheng","doi":"10.1016/j.pbiomolbio.2024.10.003","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma (OS) represents the primary form of bone cancer observed in paediatric and adolescent populations. Nearly 10%-15% of patients have metastases at diagnosis, and the 5-year survival rate was less than 20%. Although numerous investigators have offered significant efforts, the survival rates for patients with OS have remained almost unchanged over the past three decades. The most pervasive and abundant modification of internal transcripts in eukaryotic messenger RNAs (mRNAs) is N6-methyladenosine (m6A), and it is regulated by m6A methylation regulators. A number of recent studies have demonstrated that m6A modifications can regulate the biological activities of tumour cells and are intimately linked with cancer development, prognosis, drug resistance, and therapy. N6-methyladenosine modification of Non-coding RNA (ncRNA) has likewise shown a broad potential in gene regulation and tumor biology. Epigenetic changes induced by mRNAs and ncRNAs methylation are important for a better understanding of OS development and targeted drug development. Therefore, this paper summarises the biological functions of m6A-modified regulators in osteosarcoma and the role of mutual regulation between m6A and ncRNAs in osteosarcoma. Furthermore, the potential clinical applications of m6A modifications in OS are presented for consideration. It provides new directions for the future research and clinical treatment strategies of osteosarcoma.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.pbiomolbio.2024.10.003","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0

Abstract

Osteosarcoma (OS) represents the primary form of bone cancer observed in paediatric and adolescent populations. Nearly 10%-15% of patients have metastases at diagnosis, and the 5-year survival rate was less than 20%. Although numerous investigators have offered significant efforts, the survival rates for patients with OS have remained almost unchanged over the past three decades. The most pervasive and abundant modification of internal transcripts in eukaryotic messenger RNAs (mRNAs) is N6-methyladenosine (m6A), and it is regulated by m6A methylation regulators. A number of recent studies have demonstrated that m6A modifications can regulate the biological activities of tumour cells and are intimately linked with cancer development, prognosis, drug resistance, and therapy. N6-methyladenosine modification of Non-coding RNA (ncRNA) has likewise shown a broad potential in gene regulation and tumor biology. Epigenetic changes induced by mRNAs and ncRNAs methylation are important for a better understanding of OS development and targeted drug development. Therefore, this paper summarises the biological functions of m6A-modified regulators in osteosarcoma and the role of mutual regulation between m6A and ncRNAs in osteosarcoma. Furthermore, the potential clinical applications of m6A modifications in OS are presented for consideration. It provides new directions for the future research and clinical treatment strategies of osteosarcoma.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨肉瘤中的 m6A 甲基化调节因子和 ncRNA:潜在的治疗策略
骨肉瘤(Osteosarcoma,OS)是在儿童和青少年群体中观察到的主要骨癌形式。近 10%至 15%的患者在确诊时已出现转移,5 年生存率低于 20%。尽管众多研究人员付出了巨大努力,但在过去 30 年中,OS 患者的生存率几乎没有变化。真核生物信使 RNA(mRNA)内部转录本最普遍、最丰富的修饰是 N6-甲基腺苷(m6A),它受 m6A 甲基化调节因子的调控。最近的一些研究表明,m6A 修饰可调节肿瘤细胞的生物活性,并与癌症的发展、预后、耐药性和治疗密切相关。非编码 RNA(ncRNA)的 N6-甲基腺苷修饰同样显示出在基因调控和肿瘤生物学方面的广泛潜力。由 mRNA 和 ncRNA 甲基化诱导的表观遗传学变化对于更好地了解操作系统的发展和靶向药物的开发非常重要。因此,本文总结了 m6A 修饰调控因子在骨肉瘤中的生物学功能,以及 m6A 和 ncRNA 在骨肉瘤中的相互调控作用。此外,文章还提出了 m6A 修饰在 OS 中的潜在临床应用,以供思考。它为骨肉瘤的未来研究和临床治疗策略提供了新的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.30%
发文量
567
期刊最新文献
Hyperbaric oxygen treatment promotes tendon-bone interface healing in a rabbit model of rotator cuff tears. Oxygen-ozone therapy for myocardial ischemic stroke and cardiovascular disorders. Comparative study on the anti-inflammatory and protective effects of different oxygen therapy regimens on lipopolysaccharide-induced acute lung injury in mice. Heme oxygenase/carbon monoxide system and development of the heart. Hyperbaric oxygen for moderate-to-severe traumatic brain injury: outcomes 5-8 years after injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1